Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Cortés J[au]:

Acute myeloid leukaemia. Short NJ et al. Lancet. (2018)

Treatment of Relapsed/Refractory Acute Myeloid Leukemia. Bose P et al. Curr Treat Options Oncol. (2017)

4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†. Cardoso F et al. Ann Oncol. (2018)

Search results

Items: 1 to 50 of 2210

1.

TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancer.

Rugo HS, Bardia A, Tolaney SM, Arteaga C, Cortes J, Sohn J, Marmé F, Hong Q, Delaney RJ, Hafeez A, André F, Schmid P.

Future Oncol. 2020 Mar 30. doi: 10.2217/fon-2020-0163. [Epub ahead of print]

2.

Candidemia in Colombia

Cortés JA, Ruiz JF, Melgarejo-Moreno LN, Lemos EV.

Biomedica. 2020 Mar 1;40(1):195-207. doi: 10.7705/biomedica.4400. English, Spanish.

3.

Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study.

Montesinos P, Roboz GJ, Bulabois CE, Subklewe M, Platzbecker U, Ofran Y, Papayannidis C, Wierzbowska A, Shin HJ, Doronin V, Deneberg S, Yeh SP, Ozcan MA, Knapper S, Cortes J, Pollyea DA, Ossenkoppele G, Giralt S, Döhner H, Heuser M, Xiu L, Singh I, Huang F, Larsen JS, Wei AH.

Leukemia. 2020 Mar 16. doi: 10.1038/s41375-020-0773-5. [Epub ahead of print]

PMID:
32203138
4.

The Second Generation Antibody-Drug Conjugate SYD985 Overcomes Resistances to T-DM1.

Nadal-Serrano M, Morancho B, Escrivá-de-Romaní S, Morales CB, Luque A, Escorihuela M, Espinosa Bravo M, Peg V, Dijcks FA, Dokter WHA, Cortés J, Saura C, Arribas J.

Cancers (Basel). 2020 Mar 13;12(3). pii: E670. doi: 10.3390/cancers12030670.

5.

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.

Swain SM, Miles D, Kim SB, Im YH, Im SA, Semiglazov V, Ciruelos E, Schneeweiss A, Loi S, Monturus E, Clark E, Knott A, Restuccia E, Benyunes MC, Cortés J; CLEOPATRA study group.

Lancet Oncol. 2020 Mar 12. pii: S1470-2045(19)30863-0. doi: 10.1016/S1470-2045(19)30863-0. [Epub ahead of print]

PMID:
32171426
6.

Phase 2 Study of Hyper-CMAD with Liposomal Vincristine for Patients with Newly Diagnosed Acute Lymphoblastic Leukemia.

Sasaki K, Kantarjian H, Wierda W, Ravandi F, Daver N, Burger J, DiNardo CD, Jain N, Short NJ, Estrov Z, Konopleva M, Ohanian M, Garcia-Manero G, Kadia T, Alvarado Y, Yilmaz M, Pierce S, Garris R, Cortes J, O'Brien S, Ingram A, Jabbour E.

Am J Hematol. 2020 Mar 14. doi: 10.1002/ajh.25784. [Epub ahead of print]

PMID:
32170867
7.

BRAF V600E mutational load as a prognosis biomarker in malignant melanoma.

Sevilla A, Morales MC, Ezkurra PA, Rasero J, Velasco V, Cancho-Galan G, Sánchez-Diez A, Mujika K, Penas C, Smith I, Asumendi A, Cortés JM, Boyano MD, Alonso S.

PLoS One. 2020 Mar 13;15(3):e0230136. doi: 10.1371/journal.pone.0230136. eCollection 2020.

8.

Prolonged Migraine Stuttering Aura: Structural, Functional, and Video Neuroimaging Study of an Atypical Migraine Aura. A Case Report.

Rodríguez-Castro E, Lagorio AN, Bejarano-García A, Aguiar P, Cortés J, Leira R.

Headache. 2020 Apr;60(4):776-780. doi: 10.1111/head.13780. Epub 2020 Mar 5.

PMID:
32141076
9.

High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin-but not with treatment of physician's choice-in the EMBRACE study.

Miyoshi Y, Yoshimura Y, Saito K, Muramoto K, Sugawara M, Alexis K, Nomoto K, Nakamura S, Saeki T, Watanabe J, Perez-Garcia JM, Cortes J.

Breast Cancer. 2020 Mar 5. doi: 10.1007/s12282-020-01067-2. [Epub ahead of print]

PMID:
32133606
10.

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.

Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, Clark RE, Cortes JE, Deininger MW, Guilhot F, Hjorth-Hansen H, Hughes TP, Janssen JJWM, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Mayer J, Nicolini F, Niederwieser D, Pane F, Radich JP, Rea D, Richter J, Rosti G, Rousselot P, Saglio G, Saußele S, Soverini S, Steegmann JL, Turkina A, Zaritskey A, Hehlmann R.

Leukemia. 2020 Mar 3. doi: 10.1038/s41375-020-0776-2. [Epub ahead of print] Review.

PMID:
32127639
11.

Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy.

Montalban-Bravo G, Kanagal-Shamanna R, Class CA, Sasaki K, Ravandi F, Cortes JE, Daver N, Takahashi K, Short NJ, DiNardo CD, Jabbour E, Borthakur G, Naqvi K, Issa GC, Konopleva M, Khoury JD, Routbort M, Pierce S, Do KA, Bueso-Ramos C, Patel K, Kantarjian H, Garcia-Manero G, Kadia TM.

Am J Hematol. 2020 Feb 28. doi: 10.1002/ajh.25769. [Epub ahead of print]

PMID:
32112433
12.

Use of Phycobiliproteins from Atacama Cyanobacteria as Food Colorants in a Dairy Beverage Prototype.

Galetović A, Seura F, Gallardo V, Graves R, Cortés J, Valdivia C, Núñez J, Tapia C, Neira I, Sanzana S, Gómez-Silva B.

Foods. 2020 Feb 24;9(2). pii: E244. doi: 10.3390/foods9020244.

13.

Pembrolizumab for Early Triple-Negative Breast Cancer.

Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Foukakis T, Fasching PA, Cardoso F, Untch M, Jia L, Karantza V, Zhao J, Aktan G, Dent R, O'Shaughnessy J; KEYNOTE-522 Investigators.

N Engl J Med. 2020 Feb 27;382(9):810-821. doi: 10.1056/NEJMoa1910549.

PMID:
32101663
14.

A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia.

Bose P, Verstovsek S, Cortes JE, Tse S, Gasior Y, Jain N, Jabbour EJ, Estrov Z, Alvarado Y, DiNardo CD, Pemmaraju N, Kornblau SM, Kadia TM, Daver NG, Naqvi K, Short NJ, Masarova L, Villareal J, Pierce SA, Nogueras-Gonzalez G, Huang X, Garcia-Manero G, Kantarjian HM, Ravandi F.

Leukemia. 2020 Feb 25. doi: 10.1038/s41375-020-0778-0. [Epub ahead of print] No abstract available.

PMID:
32099037
15.

Photophoretic Levitation of Macroscopic Nanocardboard Plates.

Cortes J, Stanczak C, Azadi M, Narula M, Nicaise SM, Hu H, Bargatin I.

Adv Mater. 2020 Feb 20:e1906878. doi: 10.1002/adma.201906878. [Epub ahead of print]

PMID:
32080905
16.

Enhancing global access to cancer medicines.

Cortes J, Perez-García JM, Llombart-Cussac A, Curigliano G, El Saghir NS, Cardoso F, Barrios CH, Wagle S, Roman J, Harbeck N, Eniu A, Kaufman PA, Tabernero J, García-Estévez L, Schmid P, Arribas J.

CA Cancer J Clin. 2020 Feb 18. doi: 10.3322/caac.21597. [Epub ahead of print] Review.

17.

Aquatic Thermal Reservoirs of Microbial Life in a Remote and Extreme High Andean Hydrothermal System.

Pérez V, Cortés J, Marchant F, Dorador C, Molina V, Cornejo-D'Ottone M, Hernández K, Jeffrey W, Barahona S, Hengst MB.

Microorganisms. 2020 Feb 3;8(2). pii: E208. doi: 10.3390/microorganisms8020208.

18.

Long-term results of a phase 2 trial of nilotinib 400 mg twice daily in newly diagnosed patients with chronic-phase chronic myeloid leukemia.

Masarova L, Cortes JE, Patel KP, O'Brien S, Nogueras-Gonzalez GM, Konopleva M, Verstovsek S, Garcia-Manero G, Ferrajoli A, Kadia TM, Ravandi-Kashani F, Borthakur G, DellaSala S, Estrov Z, Jabbour EJ, Kantarjian HM.

Cancer. 2020 Apr 1;126(7):1448-1459. doi: 10.1002/cncr.32623. Epub 2020 Jan 30.

PMID:
31999850
19.

Long-term results of frontline dasatinib in chronic myeloid leukemia.

Maiti A, Cortes JE, Patel KP, Masarova L, Borthakur G, Ravandi F, Verstovsek S, Ferrajoli A, Estrov Z, Garcia-Manero G, Kadia TM, Nogueras-González GM, Skinner J, Poku R, DellaSala S, Luthra R, Jabbour EJ, O'Brien S, Kantarjian HM.

Cancer. 2020 Apr 1;126(7):1502-1511. doi: 10.1002/cncr.32627. Epub 2020 Jan 30.

PMID:
31999839
20.

Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer.

Jacobs SA, Robidoux A, Abraham J, Pérez-Garcia JM, La Verde N, Orcutt JM, Cazzaniga ME, Piette F, Antolín S, Aguirre E, Cortes J, Llombart-Cussac A, Di Cosimo S, Kim RS, Feng H, Lipchik C, Lucas PC, Srinivasan A, Wang Y, Song N, Gavin PG, Balousek AD, Paik S, Allegra CJ, Wolmark N, Pogue-Geile KL.

Breast Cancer Res. 2020 Jan 22;22(1):9. doi: 10.1186/s13058-019-1240-y.

21.

Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade.

Brasó-Maristany F, Griguolo G, Pascual T, Paré L, Nuciforo P, Llombart-Cussac A, Bermejo B, Oliveira M, Morales S, Martínez N, Vidal M, Adamo B, Martínez O, Pernas S, López R, Muñoz M, Chic N, Galván P, Garau I, Manso L, Alarcón J, Martínez E, Gregorio S, Gomis RR, Villagrasa P, Cortés J, Ciruelos E, Prat A.

Nat Commun. 2020 Jan 20;11(1):385. doi: 10.1038/s41467-019-14111-3.

22.

A heavy metal baseline score predicts outcome in acute myeloid leukemia.

Ohanian M, Telouk P, Kornblau S, Albarede F, Ruvolo P, Tidwell RSS, Plesa A, Kanagal-Shamanna R, Matera EL, Cortes J, Carson A, Dumontet C.

Am J Hematol. 2020 Jan 16. doi: 10.1002/ajh.25731. [Epub ahead of print]

PMID:
31944361
23.

Brain connectivity and cognitive functioning in individuals six months after multiorgan failure.

Jimenez-Marin A, Rivera D, Boado V, Diez I, Labayen F, Garrido I, Ramos-Usuga D, Benito-Sánchez I, Rasero J, Cabrera-Zubizarreta A, Gabilondo I, Stramaglia S, Arango-Lasprilla JC, Cortes JM.

Neuroimage Clin. 2020;25:102137. doi: 10.1016/j.nicl.2019.102137. Epub 2019 Dec 23.

24.

Efficacy of PI3K inhibitors in advanced breast cancer.

Verret B, Cortes J, Bachelot T, Andre F, Arnedos M.

Ann Oncol. 2019 Dec;30 Suppl 10:x12-x20. doi: 10.1093/annonc/mdz381. Review.

PMID:
31928690
25.

Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia.

Dao KT, Gotlib J, Deininger MMN, Oh ST, Cortes JE, Collins RH Jr, Winton EF, Parker DR, Lee H, Reister A, Schultz, Savage S, Stevens, Brockett C, Subbiah N, Press RD, Raess PW, Cascio M, Dunlap J, Chen Y, Degnin C, Maxson JE, Tognon CE, Macey T, Druker BJ, Tyner JW.

J Clin Oncol. 2020 Apr 1;38(10):1006-1018. doi: 10.1200/JCO.19.00895. Epub 2019 Dec 27.

PMID:
31880950
26.

Efficacy of PI3K inhibitors in advanced breast cancer.

Verret B, Cortes J, Bachelot T, Andre F, Arnedos M.

Ann Oncol. 2019 Dec 1;30(Suppl_10):x12-x20. doi: 10.1093/annonc/mdz381.

27.

Predictive clinical features of cardioembolic infarction in patients aged 85 years and older.

Carbajo-García AM, Cortés J, Arboix A, Massons J, Díez L, Vergés E, Arboix-Alió J, García-Eroles L.

J Geriatr Cardiol. 2019 Nov;16(11):793-799. doi: 10.11909/j.issn.1671-5411.2019.11.008.

28.

Treatment-free remission in chronic myeloid leukemia.

Molica M, Naqvi K, Cortes JE, Paul S, Kadia TM, Breccia M, Kantarjian H, Jabbour EJ.

Clin Adv Hematol Oncol. 2019 Dec;17(12):686-696.

PMID:
31851157
29.

Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial.

Schmid P, Abraham J, Chan S, Wheatley D, Brunt AM, Nemsadze G, Baird RD, Park YH, Hall PS, Perren T, Stein RC, Mangel L, Ferrero JM, Phillips M, Conibear J, Cortes J, Foxley A, de Bruin EC, McEwen R, Stetson D, Dougherty B, Sarker SJ, Prendergast A, McLaughlin-Callan M, Burgess M, Lawrence C, Cartwright H, Mousa K, Turner NC.

J Clin Oncol. 2020 Feb 10;38(5):423-433. doi: 10.1200/JCO.19.00368. Epub 2019 Dec 16.

PMID:
31841354
30.

Protein tyrosine phosphatase PTPN1 modulates cell growth and associates with poor outcome in human neuroblastoma.

Nunes-Xavier CE, Aurtenetxe O, Zaldumbide L, López-Almaraz R, Erramuzpe A, Cortés JM, López JI, Pulido R.

Diagn Pathol. 2019 Dec 14;14(1):134. doi: 10.1186/s13000-019-0919-9.

31.

Neoadjuvant Metformin Added to Systemic Therapy Decreases the Proliferative Capacity of Residual Breast Cancer.

Lopez-Bonet E, Buxó M, Cuyàs E, Pernas S, Dorca J, Álvarez I, Martínez S, Pérez-Garcia JM, Batista-López N, Rodríguez-Sánchez CA, Amillano K, Domínguez S, Luque M, Morilla I, Stradella A, Viñas G, Cortés J, Oliveras G, Meléndez C, Castillo L, Verdura S, Brunet J, Joven J, Garcia M, Saidani S, Martin-Castillo B, Menendez JA.

J Clin Med. 2019 Dec 11;8(12). pii: E2180. doi: 10.3390/jcm8122180.

32.

Contextualizing pertuzumab approval in the treatment of HER2-positive breast cancer patients.

Cortés J, Ciruelos E, Pérez-García J, Albanell J, García-Estévez L, Ruiz-Borrego M, Espinosa R, Gallegos I, González S, Álvarez I, Llombart A.

Cancer Treat Rev. 2020 Feb;83:101944. doi: 10.1016/j.ctrv.2019.101944. Epub 2019 Nov 29. Review.

PMID:
31830538
33.

Investigation of Lewis Acid-Carbonyl Solution Interactions via Infrared-Monitored Titration.

Hanson CS, Psaltakis MC, Cortes JJ, Siddiqi SS, Devery JJ 3rd.

J Org Chem. 2020 Jan 17;85(2):820-832. doi: 10.1021/acs.joc.9b02822. Epub 2019 Dec 27.

PMID:
31830419
34.

Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.

Hughes TP, Mauro MJ, Cortes JE, Minami H, Rea D, DeAngelo DJ, Breccia M, Goh YT, Talpaz M, Hochhaus A, le Coutre P, Ottmann O, Heinrich MC, Steegmann JL, Deininger MWN, Janssen JJWM, Mahon FX, Minami Y, Yeung D, Ross DM, Tallman MS, Park JH, Druker BJ, Hynds D, Duan Y, Meille C, Hourcade-Potelleret F, Vanasse KG, Lang F, Kim DW.

N Engl J Med. 2019 Dec 12;381(24):2315-2326. doi: 10.1056/NEJMoa1902328.

PMID:
31826340
35.

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.

Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K, Andre F, Iwata H, Ito Y, Tsurutani J, Sohn J, Denduluri N, Perrin C, Aogi K, Tokunaga E, Im SA, Lee KS, Hurvitz SA, Cortes J, Lee C, Chen S, Zhang L, Shahidi J, Yver A, Krop I; DESTINY-Breast01 Investigators.

N Engl J Med. 2020 Feb 13;382(7):610-621. doi: 10.1056/NEJMoa1914510. Epub 2019 Dec 11.

PMID:
31825192
36.

NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer.

Jacobs SA, Robidoux A, Abraham J, Pérez-Garcia JM, La Verde N, Orcutt JM, Cazzaniga ME, Piette F, Antolín S, Aguirre E, Cortes J, Llombart-Cussac A, Di Cosimo S, Kim RS, Feng H, Lipchik C, Lucas PC, Srinivasan A, Wang Y, Song N, Gavin PG, Balousek AD, Paik S, Allegra CJ, Wolmark N, Pogue-Geile KL.

Breast Cancer Res. 2019 Dec 3;21(1):133. doi: 10.1186/s13058-019-1196-y. Erratum in: Breast Cancer Res. 2020 Jan 22;22(1):9.

37.

Regional brain atrophy in gray and white matter is associated with cognitive impairment in Myotonic Dystrophy type 1.

Labayru G, Diez I, Sepulcre J, Fernández E, Zulaica M, Cortés JM, López de Munain A, Sistiaga A.

Neuroimage Clin. 2019;24:102078. doi: 10.1016/j.nicl.2019.102078. Epub 2019 Nov 6.

38.
39.

Clinical Implications of Extracellular HMGA1 in Breast Cancer.

Méndez O, Pérez J, Soberino J, Racca F, Cortés J, Villanueva J.

Int J Mol Sci. 2019 Nov 26;20(23). pii: E5950. doi: 10.3390/ijms20235950. Review.

40.

Population Pharmacokinetics of Glasdegib in Patients With Advanced Hematologic Malignancies and Solid Tumors.

Lin S, Shaik N, Martinelli G, Wagner AJ, Cortes J, Ruiz-Garcia A.

J Clin Pharmacol. 2019 Nov 25. doi: 10.1002/jcph.1556. [Epub ahead of print]

PMID:
31769065
41.

Consolidation outcomes in CPX-351 versus cytarabine/daunorubicin-treated older patients with high-risk/secondary acute myeloid leukemia.

Kolitz JE, Strickland SA, Cortes JE, Hogge D, Lancet JE, Goldberg SL, Villa KF, Ryan RJ, Chiarella M, Louie AC, Ritchie EK, Stuart RK.

Leuk Lymphoma. 2020 Mar;61(3):631-640. doi: 10.1080/10428194.2019.1688320. Epub 2019 Nov 25.

PMID:
31760835
42.

Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia.

Sasaki K, Kanagal-Shamanna R, Montalban-Bravo G, Assi R, Jabbour E, Ravandi F, Kadia T, Pierce S, Takahashi K, Nogueras Gonzalez G, Patel K, Soltysiak KA, Cortes J, Kantarjian HM, Garcia-Manero G.

Cancer. 2020 Feb 15;126(4):765-774. doi: 10.1002/cncr.32566. Epub 2019 Nov 19.

PMID:
31742675
43.

Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults: Recommendations From the European Hematology Association and the European LeukemiaNet.

Itzykson R, Fenaux P, Bowen D, Cross NCP, Cortes J, De Witte T, Germing U, Onida F, Padron E, Platzbecker U, Santini V, Sanz GF, Solary E, Van de Loosdrecht A, Malcovati L.

Hemasphere. 2018 Nov 29;2(6):e150. doi: 10.1097/HS9.0000000000000150. eCollection 2018 Dec.

44.

Prey and Venom Efficacy of Male and Female Wandering Spider, Phoneutria boliviensis (Araneae: Ctenidae).

Valenzuela-Rojas JC, González-Gómez JC, van der Meijden A, Cortés JN, Guevara G, Franco LM, Pekár S, García LF.

Toxins (Basel). 2019 Oct 27;11(11). pii: E622. doi: 10.3390/toxins11110622.

45.

New records of Swiftia (Cnidaria, Anthozoa, Octocorallia) from off the Pacific Costa Rican margin, including a new species from methane seeps.

Breedy O, Rouse GW, Stabbins A, Cortés J, Cordes EE.

Zootaxa. 2019 Sep 18;4671(3):zootaxa.4671.3.6. doi: 10.11646/zootaxa.4671.3.6.

PMID:
31716045
46.

Corrigendum to "Relationship between structural damage with loss of strength and functional disability in psoriatic arthritis patients" [Clin. Biomech. volume 68 (2019) Pages 169-174/Article Number JCLB 4795].

Olmos CMF, Alvarez-Calderon O, Marín DH, Cortés JI, Marco CP, Ivorra JAR.

Clin Biomech (Bristol, Avon). 2020 Feb;72:212. doi: 10.1016/j.clinbiomech.2019.10.023. Epub 2019 Nov 7. No abstract available.

PMID:
31708261
47.

The nucleus does not significantly affect the migratory trajectories of amoeba in two-dimensional environments.

De la Fuente IM, Bringas C, Malaina I, Regner B, Pérez-Samartín A, Boyano MD, Fedetz M, López JI, Pérez-Yarza G, Cortes JM, Sejnowski T.

Sci Rep. 2019 Nov 8;9(1):16369. doi: 10.1038/s41598-019-52716-2.

48.

The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival.

Yilmaz M, Kantarjian H, Wang X, Khoury JD, Ravandi F, Jorgensen J, Short NJ, Loghavi S, Cortes J, Garcia-Manero G, Kadia T, Sasaki K, Konopleva M, Takahashi K, Wierda W, Jain N, Verstovsek S, Estrov Z, Bose P, Pierce S, Garris R, O'Brien S, Jabbour E.

Am J Hematol. 2020 Feb;95(2):144-150. doi: 10.1002/ajh.25671. Epub 2019 Nov 19.

PMID:
31682008
49.

Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML.

Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, Montesinos P, Baer MR, Larson RA, Ustun C, Fabbiano F, Erba HP, Di Stasi A, Stuart R, Olin R, Kasner M, Ciceri F, Chou WC, Podoltsev N, Recher C, Yokoyama H, Hosono N, Yoon SS, Lee JH, Pardee T, Fathi AT, Liu C, Hasabou N, Liu X, Bahceci E, Levis MJ.

N Engl J Med. 2019 Oct 31;381(18):1728-1740. doi: 10.1056/NEJMoa1902688.

PMID:
31665578
50.

Agreement between results of meta-analyses from case reports and clinical studies, regarding efficacy and safety of idursulfase therapy in patients with mucopolysaccharidosis type II (MPS-II). A new tool for evidence-based medicine in rare diseases.

Sampayo-Cordero M, Miguel-Huguet B, Pardo-Mateos A, Malfettone A, Pérez-García J, Llombart-Cussac A, Cortés J, Moltó-Abad M, Muñoz-Delgado C, Pérez-Quintana M, Pérez-López J.

Orphanet J Rare Dis. 2019 Oct 21;14(1):230. doi: 10.1186/s13023-019-1202-6.

Supplemental Content

Loading ...
Support Center